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An emerging problem
urinary tract disease associated 
with chronic ketamine use
Regarding the case study by Dhillon et al,1 
we have seen an alarming increase in people 
presenting to urological services in South West 
England with bladder symptoms associated 
with chronic ketamine use. Two case series in 
Hong Kong and Canada have been published, 
but ketamine associated bladder pathology has 
not been reported in the UK.2 3
Over the past two years, nine patients have 
presented to local urologists with symptoms of 
severe urinary frequency, urgency, macroscopic 
haematuria, and suprapubic pain. They all 
had a history of chronic ketamine use, either 
recreationally or therapeutically for chronic 
pain. Urine culture results were negative and 
cystoscopy showed a contracted shrunken 
bladder with erythema and contact bleeding. 
Histological examination showed ulcerative 
cystitis and a severely denuded urothelium.
They were given analgesics and encouraged 
not to use ketamine. Complications included 
hydronephrosis and renal impairment. They 
were treated by nephrostomy and insertion of 
a suprapubic catheter to manage painful urge 
urinary incontinence.
Discussions with the patients and contact 
with Bristol Drugs Project indicated that 
these cases are just the “tip of the iceberg.” 
Recreational use of ketamine is increasing in 
the West Country. Urinary symptoms are often 
reported by ketamine users. Symptoms may 
improve and even reverse once ketamine intake 
is stopped, but two of our patients still have 
intractable symptoms despite abstaining. The 
pathological mechanism of ketamine is not 
known, but chronic ketamine use may affect 
the whole urinary tract. Some patients have 
acute renal failure, renal papillary necrosis, 
and ureteric obstruction (Peggy Chu, personal 
communication). Further work is needed to 
establish the mechanism of action of ketamine 
on the urinary tract and to educate healthcare 
professionals who may come in contact with 
these patients. Ketamine users must be made 
aware of the serious and potentially irreversible 
sequelae of chronic ketamine use, and we are 
working with Bristol Drugs Project to develop 
evidence based harm reduction advice for this 
population.
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ConfidentiAlity
Communications with primary 
care trusts: another challenge
Bourke and Wessely are to be commended 
for their useful summary of medical 
confidentiality.1 However, there is a new 
challenge in this area—communication with 
primary care trusts and other organisations that 
control funding of clinical care. A secretary in my 
NHS trust was ordered by an administrator from 
a nearby primary care trust to forward a clinic 
letter on a patient whom I had assessed in my 
neuropsychiatry clinic, so that the trust could 
decide whether a follow-up appointment was 
to be “authorised.” We were told that failure 
to forward the letter would prevent the patient 
from being seen again. No account was taken 
of the sensitivity of information contained in 
the letter. There was no reference to obtaining 
the patient’s consent. The primary care trust 
representative was not a clinician and was not 
writing on behalf of a clinician. Neither she nor 
the primary care trust formed part of the clinical 
team, and the decision they were making was 
not necessarily in the patient’s interest—it was 
purely about funding.
It is ironic that in these times where legitimate 
access to patient information for research 
purposes is becoming ever more difficult, 
ostensibly to protect patient confidentiality, 
flagrant breaches are being made in the service 
of financial control.
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sCreening for AortiC Aneurysm
Detection is not as harmful as it 
might seem
Johnson argues that screening for abdominal 
aortic aneurysm may cause psychological 
harm by alerting people that they have a 
condition that nothing can be done about but 
that can cause sudden death.1 This notion 
is contradicted by a large literature on how 
people respond to aneurysm screening2 and 
other health risk information.3 It is also at odds 
with psychological theories of self regulation, 
which describe the complex ways that humans 
maintain equilibrium while responding to all 
sorts of threats.
Anxiety is a common and adaptive initial 
response to risk notification, but it usually 
dissipates within a month.3 Pretest preparation 
can mitigate anxiety, but there is no evidence 
to support the statement that “any member of 
the public taking the test will need intensive 
counselling about the possible consequences 
that screening might have for their future lives 
and psychological wellbeing.”1 The way people 
think and feel before screening seems to be a 
stronger predictor of post screening states than 
test results—those who are depressed before 
screening are depressed afterwards, whatever 
the results.4 Poorer self assessed health seems 
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unexpected, agonising, and bloody deaths.
Detection of an abdominal aortic aneurysm 
provides one important benefit that Johnson 
ignores—patient choice. Patients who die 
of rupture are denied that choice. Johnson 
suggests that screening leads to unacceptable 
levels of anxiety for those placed on surveillance 
programmes. This claim is not supported by 
the literature. Screening for abdominal aortic 
aneurysm also compares favourably, in cost 
effectiveness terms, with breast and cervical 
screening.
I suspect that the government has not funded 
abdominal aortic aneurysm screening (and 
even now provides only lukewarm support) 
because few votes will be won (and more 
pensions will need to be paid) by saving the 
lives of men of retirement age. As a politician, 
Johnson should understand this all too well.
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No conclusion for men aged 
65-75 who have never smoked
Brearley cites the US Preventive Services Task 
Force (USPSTF) in support of abdominal aortic 
aneurysm screening.1 However, it makes no 
recommendation for or against screening in 
men aged 65-75 who have never smoked. 
The task force did find good evidence that 
screening in these men leads to decreased 
abdominal aortic aneurysm specific mortality, 
but they have a lower prevalence of large 
abdominal aortic aneurysms than men who 
have ever smoked, so the potential benefit is 
small. There is good evidence that screening 
and early treatment lead to important harms, 
including increased number of operations 
with associated clinically significant morbidity 
and mortality, and short term psychological 
harm. The task force concluded that the 
balance between the benefits and harms of 
screening for abdominal aortic aneurysm is 
too close to make a general recommendation 
in this population.2
The men invited for screening should be 
given this information as well as the likelihood 
that they will benefit—less than one in 1000. 
Consent for screening is only valid if it is well 
informed.
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globAl ACCess to vACCines
Vaccine science and commerce: 
never the twain shall meet?
Chokshi and Kesselheim suggest some reasons 
why effective vaccines are unavailable in poorer 
countries.1 The main reason is that most wealthy 
countries demand a solution (vaccine) for 
infectious diseases of public health importance, 
while poorer countries do not—and should they 
do so, they are largely ignored. This explains 
the scant attention paid to important issues 
such as improving measles and tuberculosis 
vaccines and the strong focus on new vaccines 
irrespective of their desirability and feasibility 
in developing countries. What is worse is that 
many manufacturers have realised the potential 
of marketing in developing countries (large 
population and variable spending power) and 
are ruthlessly exploiting the weak decision 
making systems there to aggressively promote 
products that are often not required.
Chokshi and Kesselheim state that “difficulty 
in disseminating well established vaccines 
casts doubts on our ability to promote 
widespread use of new ones,”1 but the opposite 
is being witnessed in most developing countries 
today. Although coverage with vaccines such as 
against diphtheria, pertussis, and tetanus and 
measles have still not reached levels required 
to eradicate/eliminate/control these “old” 
problems, new vaccines are being aggressively 
promoted not only by manufacturers but also 
directly and indirectly by trusted organisations 
such as the World Health Organization, national 
bodies of experts, and perhaps articles such as 
Chokshi and Kesselheim’s.
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Poor nations are being lured 
into a debt trap
With regard to access to papillomavirus vaccine 
(Gardasil),1 let us assume that the vaccine 
covers all strains causing cervical cancer. In 
India 21m girls would have to be vaccinated 
each year to avoid 260 000 deaths at a cost for 
the vaccine alone of $8400m. The programme 
would have to be sustained for over 20 years. 
Even if it prevented all cervical cancers, it would 
reduce by only 2% the 10.9m deaths caused by 
infectious diseases.2 If the cost of the vaccine 
fell to $1 per dose, it would still cost $63m for 
the vaccine alone.
to be a predictor not a consequence of the 
detection of an aneurysm.5
Not everyone participates or responds to 
questionnaires on emotional states. People who 
do not respond seem to have poorer emotional 
outcomes. However, the large robust studies 
that have assessed emotional outcomes after 
detection of an aneurysm provide no evidence 
to suggest that this generates psychological 
harm of the kind imagined by Johnson.
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Some reasons for lukewarm 
support are purely political
Johnson argues that a death rate of one in 14 
from elective abdominal aortic aneurysm repair 
means that screening is futile.1 Many specialist 
vascular units have elective mortality rates of 5% 
or less for open repair and mortality rates of less 
than 2% for endovascular repair (as confirmed 
by the EVAR trial and Dr Foster). Even a one in 
14 death rate is better than 80% mortality from 
rupture. I and many of my colleagues (including 
nursing staff) are weary of counselling the 
grieving wives and children of men who suffer 
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Vaccine sale is not tailored to 
improving India’s health
Measles is still a big killer, especially in 
poor malnourished children in India. Yet 
professional bodies have yet to recommend to 
the government the inclusion of the measles, 
mumps, and rubella (MMR) vaccine in the 
national immunisation programme.1 The 
Indian Academy of Paediatrics has, however, 
recommended vaccination against hepatitis 
B. The incidence of hepatitis B in India is 
lower than originally thought, so the costs of 
vaccination may outweigh the benefits and its 
inclusion in the national programme may not be 
justified.
Vaccination against Haemophilus influenzae 
type B is also being promoted aggressively 
by drug companies with the acquiescence of 
professional academies. Infections, especially 
meningitis, caused by haemophilus influenza 
in young children are serious, causing a 
high proportion of death and disability. The 
epidemiology of haemophilus influenza in 
India and its incidence in Indian children are 
not known, so the recommendations have been 
made without a risk-benefit analysis.
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Vaccine requirements compete 
with basic needs of poor people
Chokshi and Kesselheim make a strong case for 
developing countries to invest in an evidence 
base for developing and appropriately using 
newer vaccines.1 However, an infrastructure of 
the required research and information systems 
is entirely absent in developing countries 
and its creation would require the complete 
revamping of current  public health systems. 
Those who promote vaccines as the most cost 
effective interventions for poor people never 
take into account the costs of erecting the 
health systems to deliver them and monitor 
their efficacy and safety.
The authors quote Amartya Sen to show the 
opportunities that open up for poor people 
in developing countries from modern health 
systems with delivery of vaccines. However, 
these people have competing needs for food, 
shelter, water, sanitation, and education. In 
reality, vaccines compete with these other 
needs. One example is that the widely prevalent 
malnutrition in children in India results from lack 
of health education of their mothers because 
health workers are too busy delivering vaccines. 
Therefore we have some improvement in vaccine 
coverage in the last two decades in India while 
malnutrition in children has not declined.
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The lessons of history
Chokshi and Kesselheim imply that the beliefs 
are unfounded of those who “believe that 
ensuring supplies of food and clean water and 
building roads will do more for public health 
than isolated interventions like vaccines.”1 
We need only brush up on some history: in the 
United States the sharp decline in mortality 
due to infectious diseases, the main cause of 
death there in the early part of the 20th century, 
happened before the specific medical technology 
for each infectious disease had developed.2
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surgery for pilonidAl diseAse
articles point to the creation of 
a cartel
It seems that Bascom, an enthusiast for the 
distinctly unproven hair follicle theory, has 
been “suckered” into believing that the midline 
wound in pilonidal sinus surgery is the cause 
of the problem.1 McCallum et al’s analysis of a 
rag bag of papers includes, disgracefully, some 
that reached their conclusions on the basis of 
telephone follow-up.2 That’s no way to conduct 
proper research. Effectively, McCallum et al took 
a load of apples, oranges, and pears and tried to 
decide which was the “best” fruit. Fruitless! For 
example, they inform us that “recurrences after 
primary closure were higher.” Of course they 
were. It is a much more demanding procedure 
in which ideally the full extent of the infected 
pilonidal sinus track needs to be stained and 
excised meticulously, but rarely is.
Pilonidal sinus surgery demands attention 
to the precise definition of the extent of 
the disease, good tissue care, haematoma 
avoidance, sterility, meticulous closure, and 
military precision in postoperative nursing. It also 
requires a regimen for preventing recurrence, 
with full patient advice and monitoring, rather 
So rotavirus causes 440 000 deaths each 
year.1 If we have a vaccine that covers all the 
human strains (an overgenerous assumption for 
India3), 126m children around 2 months of age 
will need to be vaccinated three times (378m 
doses).2 At the present public sector cost of $7/
dose4 the cost of the vaccine will be $7938m. 
This expenditure will bring down the deaths due 
to infections by 4%.
The compulsion to increase demand for these 
vaccines comes from the manufacturers not the 
consumer. That is why organisations such as 
GAVI have to give grants in aid to poor countries 
to offload these vaccines. It is hoped that 
poor countries can be persuaded to continue 
to use the vaccine after the aid is withdrawn. 
Poor nations are lured into a debt trap by such 
schemes.
Traditionally vaccines are tested by 
multinational manufacturers in the United 
States and Europe and then in developing 
countries as supplies and competition increase 
and the cost of vaccine comes down. This is in 
accordance with the Helsinki Declaration that 
trials be done in populations who are directly to 
use the drug.
Chokshi and Kesselheim point out that 
Gardasil was produced in the United States 
and Australia and tested in Brazil, India, and 
Costa Rica.1 The cost of research is halved by 
conducting it in developing countries,5 and the 
compensation for adverse events is much lower. 
In an upside down world where profits are 
paramount, this arrangement “could help meet 
international demand for low cost products.”1 
The fates of human guinea pigs in developing 
countries don’t count for much.
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than the speedy discharge or follow-up by phone 
that seemed to satisfy the authors.
It now seems that those of us who practise 
those principles will be ostracised unless we 
are on the Pilonidal Support Foundation’s list of 
58 surgeons who are “familiar with off-midline 
repairs.” No doubt, patients will be encouraged 
to ask for our credentials. On the basis of such 
flimsy evidence, that sounds worryingly like the 
creation of a cosy cartel.
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reproduCtive liberty And deAfness
Clause 14(4)(9) of embryo bill 
should be amended or deleted
Amendments to the Human Fertilisation and 
Embryology Act 1990 are currently passing 
through the UK Houses of Parliament.1 Clause 14, 
section 4, number 9 (lines 23-30, page 10) says 
that people or embryos known to have a gene, 
chromosome, or mitochondrion abnormality that 
confers a significant risk of serious physical or 
mental disability, serious illness, or other serious 
medical condition must not be preferred over 
those not known to have an abnormality.
This clause has been added to prevent positive 
selection of deaf donors deliberately to result in a 
deaf child, and one outcome would be that deaf 
parents could not use preimplantation diagnosis 
to select embryos with genes for deafness.
If passed, the bill would make it illegal for 
a deaf adult to donate gametes for in vitro 
fertilisation, even to close relatives. It would be 
illegal for deaf parents, using preimplantation 
genetic diagnosis, to implant embryos with 
the genes for deafness if normal embryos were 
available.
Actively selecting for deafness is controversial. 
However, research indicates that few people 
want to do this,2 3 and requests to clinics for 
the selection of “disability” are low.4 So, is it 
necessary to legislate against something that 
is unlikely to happen and for which guidelines 
already exist?
This section of clause 14(4)(9) is 
discriminatory. The wording implies that 
deaf people are less valuable than “hearing” 
people, and likewise for their embryos. This 
contradicts attempts by the UK government 
to recognise the equal status of deaf people 
in policy (through recognising British sign 
language) and in law (through equal rights 
for deaf people). Deaf people wish to have 
equal rights when making decisions about 
reproduction, even when genetic technology 
is involved. We are therefore arguing for 
this section of the clause to be amended or 
omitted from the UK Human Fertilisation and 
Embryology Bill.
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niCe on infeCtive endoCArditis
a call for national monitoring of 
antibiotic prophylaxis
The UK National Institute for Health and Clinical 
Excellence (NICE) recently published guidelines 
on antibiotic prophylaxis for preventing 
infective endocarditis in high risk patients with 
structural heart disease.1 2 The guidelines no 
longer recommend their use during dental and 
other invasive procedures of the respiratory 
tract, genitourinary tract, and upper and lower 
gastrointestinal tract—a considerable change 
from current practice. The guidelines apply to 
all high risk patients. The guidelines point to 
the lack of high quality evidence on whether 
antibiotics are effective in this situation or 
whether such procedures are linked to infective 
endocarditis. This was also highlighted in other 
recent guidelines,3 but they stopped short of 
recommending a change to current practice. 
This raises questions and anxiety in patients 
and those who treat them.
The report cites reactions to antibiotics 
(including anaphylaxis) as an argument 
against their use on a population scale, but 
in practice cardiologists can ask individual 
patients about previous antibiotic use and 
reactions.
Unlike most areas where NICE issues 
guidance, there are no randomised control 
trials on antibiotic prophylaxis for infective 
endocarditis. Small observational and case-
control studies provide inconclusive evidence 
in favour of antibiotic prophylaxis. Infective 
endocarditis is not a notifiable disease 
in the UK and we know of no system that 
could accurately detect a rise in incidence 
on a national level corrected for the use of 
antibiotic prophylaxis in individual cases.
Infective endocarditis is a life threatening 
condition with overall mortality of around 20%.1 
We call for a system that can robustly assess the 
outcome of this important change in practice to 
be in place alongside its implementation.
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